We are monitoring the impact of COVID-19 on Solid Tumor Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6290
Share on
Share on

Global Solid Tumor Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease, Drugs and Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6290
Pages: 175

Solid Tumor Market Size (2021 to 2026)

The global solid tumor market size is expected to witness a robust CAGR during the forecast period.

Solid tumors are formed due to the aggregation of abnormal tissues that do not comprise any cyst or liquid areas within. They are mainly of two types- malignant and benign. Most solid tumors are treated via radiotherapy, chemotherapy, or surgery. Various chemotherapeutic drugs are available in the market, along with a ripe pipeline of drugs that will soon be commercialized.

MARKET DRIVERS:

The rise in the number of cancer cases and increasing incidences of several cases of solid tumors are majorly driving the global solid tumor market growth.

Due to the increase in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents, which drives the global solid tumor market. Many companies are investing in various R&D projects related to therapeutics, which fuels market growth. An increase in demand for highly effective chemotherapeutic agents and the ripe availability pipeline of drugs in the global market is expected to propel the substantial tumor market. Lung, colorectal, liver, and breast cancers are spreading enormously; as per the records, approximately 8.2 million people died; this is expected to increase during the forecast period. Major drugs such as Afinitor (everolimus), Tarceva (erlotinib), Taxotere (docetaxel), Doxorubicin, and (Avastin bevacizumab) are available in the global market and being utilized in clinical trials are expected to boost the market growth. These products are soon to be commercialized globally and further augment the market growth. Moreover, rising government initiatives to create cancer awareness among the people and increase healthcare infrastructure influence market growth.

Additionally, advancements in the treatment techniques, such as targeted and combination therapies that include Kadcyla and Herceptin for breast cancer, provide growth opportunities for the solid tumor market. Either as a single agent or as a combination, the safety profile of vaccines represents excellent opportunities. The rise in the number of people suffering from cancer disease is lucratively fuelling the solid tumor market demand. Government initiative steps are also additionally accelerating the growth of this market.

MARKET RESTRAINTS:

However, increasing generic products, the high cost of therapy, the rising cost of R&D, and various drugs going off-patent, are turning out to be restraints for the global solid tumor market. Stringent government regulatory reforms over the solid tumor and generic competition are leading to the price erosion are the factors hindering the solid tumor market growth over the forecast period.

Impact of COVID-19 on the global solid tumor market:

The World health organization proclaimed the spread of the virus to be a pandemic. COVID-19 is an infectious disease caused by the most recent novel coronavirus, which transmits quickly from person to person. COVID-19 was first identified in Wuhan, China. COVID-19 was first arrived as a regional pandemic and turned into a global pandemic. Due to a sudden surge in virus transmission, the world health organization announced specific guidelines to stop the virus's spread. Governments imposed nationwide lockdown and ban of flights to spread the migrants from the foreign countries.

The unexpected emergence of COVID-19 has positively and negatively impacted the pharmaceutical and global sciences industries. The effects of the pandemic, the winding down of the worldwide science market have both harmed the operations and financial results of many industry participants, such as a solid tumor.

During the first quarter of 2020, the solid tumor market had a growth decline because of the surge in virus prevalence and the nationwide lockdown. During the Outbreak period, the focus of the nation was to combat the virus. Solid testing tumor procedures had been postponed as the rise in the covid-19 cases. Solid tumor treatment had not been performed due to the unavailability of healthcare professionals.

However, the uplift of lockdown has increased the market growth due to the resumed reliable tumor procedures. The hospitals started treating cancer patients. The chemotherapy market is currently holding the global market with a dominant share. However, the solid tumor market is projected to have better growth in the coming years.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Disease, Drugs, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This market research report on the global solid tumor market has been segmented and sub-segmented based on the disease, drugs, and region.

Solid Tumor Market – By Disease:

  • Breast cancer        
  • Lung cancer           
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Others      

Based on disease type, breast cancer and prostate cancer are expected to contribute the most significant share value due to the increasing occurrence rates of the diseases. In the present situation, surgery is mainly the preferred treatment for cancer solid tumors. Chemotherapy is one of the surgeries which is primarily preferred along with other modes like radiation.

Solid Tumor Market – By Drugs:

  • Carboplatin            
  • Cisplatin  
  • Gemcitabine          
  • Paclitaxel
  • Doxorubicin           
  • Bevacizumab         
  • Erlotinib   
  • Sunitinib  
  • Everolimus           
  • Docetaxel            
  • Abiraterone         
  • Abiraterone acetate         
  • Cabazitaxel

Solid Tumor Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

The global solid tumor market was dominated by North America, followed by Europe. Asia Pacific is a lucrative market and is expected to grow at a high CAGR.

North America is leading with the highest shares of the Global Solid Tumor Market. The factors driving the market are the high occurrence rate of solid cancer cases with well-equipped healthcare infrastructure. Following North America, Europe is ruling with dominant shares of the market.

Asia-Pacific is anticipated to have the fastest growth due to the rapidly developing medical infrastructure, rising medical tourism, and increased expenditure. Countries like India and China are creating awareness over the availability of the treatment procedures, setting up growth opportunities for market growth.

KEY MARKET PARTICIPANTS:

Key market participants leading the Global Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi.

KEY HAPPENINGS IN THIS MARKET:

  • In January 2020, Amgen made a public statement that it is going to collaborate with two business-lading diagnostic companies, Guardant and QIAGEN N.V., to develop the blood- tissue companion diagnostics. The agreement between the companies will focus on non-small cell lung cancer treatment procedures.
  • In March 2020, the liver cancer drug officially received approval from the FDA, which Bristol-Myers Squibb Company introduced.
  • In June 2019, Roche made a public statement that the combination of Tecentriq, Avastin, carboplatin, and paclitaxel showed positive results in patients suffering from liver metastases.
  • In December 2019, two major companies, Innovent and Eli Lilly and Company, collectively presented their Tyvyt. The medicine works to restore the patient's tumor T-cell response. The result between the two companies provides patients with effective and protected treatment solutions to fight against cancer.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                   

               1.3 Base Currency, Base Year and Forecast Periods                           

               1.4 General Study Assumptions                  

2. Research Methodology                                          

               2.1 Introduction               

               2.2 Research Phases                      

                              2.2.1 Secondary Research            

                              2.2.2 Primary Research  

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation   

               2.3 Analysis Design                         

               2.4 Study Timeline                          

3. Overview                                     

               3.1 Executive Summary                 

               3.2 Key Inferences                          

               3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                        

               4.1 Market Drivers                         

               4.2 Market Restraints                    

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market                 

5. Market Segmentation                              

               5.1 Disease                       

                              5.1.1 Introduction           

                              5.1.2 Breast cancer         

                              5.1.3 Lung cancer            

                              5.1.4 Colorectal cancer  

                              5.1.5 Prostate cancer     

                              5.1.6 Cervical cancer      

                              5.1.7 Others       

                              5.1.8  Y-o-Y Growth Analysis, By disease 

                              5.1.9  Market Attractiveness Analysis, By disease 

                              5.1.10  Market Share Analysis, By disease

               5.2 Drugs                           

                              5.2.1 Introduction           

                              5.2.2 Carboplatin             

                              5.2.3 Cisplatin   

                              5.2.4 Gemcitabine           

                              5.2.5 Paclitaxel 

                              5.2.6 Doxorubicin            

                              5.2.7 Bevacizumab          

                              5.2.8 Erlotinib    

                              5.2.9 Sunitinib   

                              5.2.10 Everolimus            

                              5.2.11 Docetaxel             

                              5.2.12 Abiraterone          

                              5.2.13 Abiraterone acetate          

                              5.2.14 Cabazitaxel           

                              5.2.15 Y-o-Y Growth Analysis, By Drugs   

                              5.2.16 Market Attractiveness Analysis, By drugs   

                              5.2.17 Market Share Analysis, By drugs    

6. Geographical Analysis                              

               6.1 Introduction               

                              6.1.1 Regional Trends     

                              6.1.2 Impact Analysis      

                              6.1.3 Y-o-Y Growth Analysis         

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By disease

                                             6.1.3.3 By drugs

                              6.1.4  Market Attractiveness Analysis       

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By disease

                                             6.1.4.3 By drugs

                              6.1.5  Market Share Analysis        

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By disease

                                             6.1.5.3 By drugs

               6.2 North America                          

                              6.1.1 Introduction           

                              6.1.2 United States         

                              6.1.3 Canada     

               6.3 Europe                        

                              6.2.1 Introduction           

                              6.2.2 U.K            

                              6.2.3 Spain         

                              6.2.4 Germany  

                              6.2.5 Italy           

                              6.2.6 France       

               6.4 Asia-Pacific                

                              6.3.1 Introduction           

                              6.3.2 China         

                              6.3.3 India          

                              6.3.4 Japan        

                              6.3.5 Australia   

                              6.3.6 South Korea            

               6.5 Latin America                           

                              6.4.1 Introduction           

                              6.4.2 Brazil         

                              6.4.3 Argentina 

                              6.4.4 Mexico     

                              6.4.5 Rest of Latin America          

               6.6 Middle East & Africa               

                              6.5.1 Introduction           

                              6.5.2 Middle-East            

                              6.5.3 Africa        

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis              

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services  

                              7.2.5 Competitive Rivalry within the Industry        

8. Market Leaders' Analysis                                        

               8.1 Abbott Laboratories                

                              8.1.1 Overview  

                              8.1.2 Product Analysis    

                              8.1.3 Financial analysis   

                              8.1.4 Recent Developments         

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View           

               8.2 Boehringer Ingelheim GmbH                

               8.3 Baxter International                

               8.4 Bristol-Myers Squibb Company                           

               8.5 F. Hoffmann-La Roche Ltd.                  

               8.6 Eli Lilly and Company                             

               8.7 Johnson & Johnson                 

               8.8 GlaxoSmithKline plc                 

               8.9 Kyowa Hakko Kirin Co., Ltd.                 

               8.10 Sanofi                        

9. Competitive Landscape                                          

               9.1 Market share analysis                            

               9.2 Merger and Acquisition Analysis                         

               9.3 Agreements, collaborations and Joint Ventures                           

               9.4 New Product Launches                          

10. Market Outlook and Investment Opportunities                                           

Appendix                                          

               a) List of Tables                

               b) List of Figures              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Disesase and Drugs  along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Solid Tumor Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  3. Global Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  11. Global Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  18. Global Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Others Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  22. North America Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  23. North America Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  30. North America Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  33. North America Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  36. North America Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  37. North America Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  38. North America Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  40. United States Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  41. United States Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  42. Canada Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  43. Canada Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  44. Europe Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  45. Europe Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  46. Europe Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  47. Europe Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  48. Europe Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  49. Europe Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  50. Europe Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  51. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  52. Europe Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  53. Europe Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  54. Europe Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  55. Europe Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  56. Europe Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  57. Europe Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  58. Europe Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  59. Europe Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  60. Europe Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  61. Europe Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  62. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  63. U.K. Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  64. U.K. Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  65. Germany Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  66. Germany Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  67. France Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  68. France Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  69. Italy Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  70. Italy Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  71. Spain Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  72. Spain Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  73. Asia Pacific Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  74. Asia Pacific Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  75. Asia Pacific Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  76. Asia Pacific Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  77. Asia Pacific Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  78. Asia Pacific Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  79. Asia Pacific Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  80. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  81. Asia Pacific Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  82. Asia Pacific Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  83. Asia Pacific Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  84. Asia Pacific Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  85. Asia Pacific Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  86. Asia Pacific Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  87. Asia Pacific Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  88. Asia Pacific Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  89. Asia Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  90. Asia Pacific Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  91. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  92. Japan Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  93. Japan Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  94. China Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  95. China Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  96. India Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  97. India Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  98. Australia Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  99. Australia Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  100. South Korea Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  101. South Korea Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  102. Latin America Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  103. Latin America Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  104. Latin America Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  105. Latin America Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  106. Latin America Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  107. Latin America Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  108. Latin America Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  109. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  110. Latin America Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  111. Latin America Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  112. Latin America Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  113. Latin America Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  114. Latin America Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  115. Latin America Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  116. Latin America Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  117. Latin America Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  118. Latin America Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  119. Latin America Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  120. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  121. Brazil Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  122. Brazil Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  123. Argentina Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  124. Argentina Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  125. Mexico Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  126. Mexico Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  127. Rest of Latin America Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  128. Rest of Latin America Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  129. Middle East and Africa Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  130. Middle East and Africa Breast cancer Market, By Region, From 2021 to 2026 (USD Billion)
  131. Middle East and Africa Lung cancer Market, By Region, From 2021 to 2026 (USD Billion)
  132. Middle East and Africa Liver cancer Market, By Region, From 2021 to 2026 (USD Billion)
  133. Middle East and Africa Colorectal cancer Market, By Region, From 2021 to 2026 (USD Billion)
  134. Middle East and Africa Cervical cancer Market, By Region, From 2021 to 2026 (USD Billion)
  135. Middle East and Africa Prostate cancer Market, By Region, From 2021 to 2026 (USD Billion)
  136. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  137. Middle East and Africa Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  138. Middle East and Africa Carboplatin Market, By Region, From 2021 to 2026 (USD Billion)
  139. Middle East and Africa Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  140. Middle East and Africa Doxorubicin Market, By Region, From 2021 to 2026 (USD Billion)
  141. Middle East and Africa Paclitaxel Market, By Region, From 2021 to 2026 (USD Billion)
  142. Middle East and Africa Erlotinib Market, By Region, From 2021 to 2026 (USD Billion)
  143. Middle East and Africa Suntinib Market, By Region, From 2021 to 2026 (USD Billion)
  144. Middle East and Africa Everolimus Market, By Region, From 2021 to 2026 (USD Billion)
  145. Middle East and Africa Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  146. Middle East and Africa Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Billion)
  147. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  148. Middle East Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  149. Middle East Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)
  150. Africa Solid Tumor Market, By Disease, From 2021 to 2026 (USD Billion)
  151. Africa Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample